Search Result

Results for "

Raji

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (2) Akt (1) Androgen Receptor (1) Apoptosis (13) Autophagy (1) Btk (2) CD19 (1) CD20 (1) CD28 (1) CD38 (1) CD47 (5) COX (3) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) Drug Derivative (3) EBV (10) Epigenetic Reader Domain (4) Epoxide Hydrolase (1) Estrogen Receptor/ERR (1) Fc Receptor (FcR) (2) Haspin Kinase (1) IFNAR (1) IMPDH (1) Interleukin Related (3) JAK (2) LAG-3 (1) MALT1 (1) MHC (1) Monocarboxylate Transporter (1) NADPH Oxidase (1) NO Synthase (2) PARP (1) PI3K (2) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (3) PROTACs (3) Reactive Oxygen Species (ROS) (2) Reference Standards (2) STAT (1) Topoisomerase (1)
By Research Areas:	Cancer (48) Infection (11) Inflammation/Immunology (11) Metabolic Disease (1) Neurological Disease (4)

By Targets:

ADC Payload (2)

Akt (1)

Androgen Receptor (1)

Apoptosis (13)

Autophagy (1)

Btk (2)

CD19 (1)

CD20 (1)

CD28 (1)

CD38 (1)

CD47 (5)

COX (3)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (1)

Drug Derivative (3)

EBV (10)

Epigenetic Reader Domain (4)

Epoxide Hydrolase (1)

Estrogen Receptor/ERR (1)

Fc Receptor (FcR) (2)

Haspin Kinase (1)

IFNAR (1)

IMPDH (1)

Interleukin Related (3)

JAK (2)

LAG-3 (1)

MALT1 (1)

MHC (1)

Monocarboxylate Transporter (1)

NADPH Oxidase (1)

NO Synthase (2)

PARP (1)

PI3K (2)

Platelet-activating Factor Receptor (PAFR) (1)

Polo-like Kinase (PLK) (3)

PROTACs (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

STAT (1)

Topoisomerase (1)

By Research Areas:

Cancer (48)

Infection (11)

Inflammation/Immunology (11)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12137

Volasertib Maximum Cited Publications 35 Publications Verification BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Payload	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-P99706

Ligufalimab 1 Publications Verification AK 117	CD47 Interleukin Related	Cancer
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .

HY-107260

Lucidenic acid D Lucidenic acid D2	NO Synthase COX	Infection Inflammation/Immunology Cancer
Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention .

HY-P99533

Urabrelimab 1 Publications Verification SRF-231; SRF231	CD47 Interleukin Related	Cancer
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .

HY-133131

PROTAC BRD4 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression .

HY-B2117

Valpromide	Epoxide Hydrolase EBV	Infection Neurological Disease
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28 Apoptosis	Cancer
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .

HY-18974

MCT1-IN-2 1 Publications Verification	Monocarboxylate Transporter	Cancer
MCT1-IN-2 is a potent monocarboxylate transporter 1 (MCT1) inhibitor. MCT1-IN-2 has anti-cancer activity .

HY-12137A

Volasertib trihydrochloride Maximum Cited Publications 35 Publications Verification BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-133136

PROTAC BRD4 Degrader-2	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 14.2 nM against BRD4 BD1 .

HY-W743654

Capsorubin	Apoptosis	Cancer
Capsorubin is a carotenoid found in peppers with multiple biological activities. Capsorubin (167 μM) inhibits lipid peroxidation induced by 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) in vitro. Capsorubin (1 μM) reduces UVB-induced DNA strand breaks and apoptosis in human dermal fibroblasts. Capsorubin also inhibits Epstein-Barr virus early antigen (EBV-EA) activation induced by phorbol 12-myristate 13-acetate in Raji cells, a marker of tumorigenesis.

HY-P990870

Anti-CD19 Antibody (4G7)	CD19 IFNAR Interleukin Related	Inflammation/Immunology
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-168936

DP-15	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
DP-15 is the degrader for GSPT1 and BRD4 with DC₅₀s of 5.25 nM and 0.48 nM. DP-15 exhibits anti-proliferative activity of AML cells and NHL cells with an IC₅₀ of nanomolar levels, arrests the cell cycle at G1 phase, and induces apoptosis in MOLM13. DP-15 exhibits anti-leukemia activity in MOLM-13 xenograft mouse models . (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W262798); Blue: ligand for E3 ligase Cereblon Thalidomide-5-OH (HY-23095))

HY-137257

Carbamyl-PAF C-PAF	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
Carbamyl-PAF is an analog and agonist of platelet-activating factor (PAF). Carbamyl-PAF is not significantly metabolized by Raji lymphoblasts at 37°C, making it a useful tool for inflammation research. .

HY-P990189

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

HY-W743654R

Capsorubin (Standard)	Apoptosis Reference Standards	Cancer
Capsorubin (Standard) is the analytical standard of Capsorubin. This product is intended for research and analytical applications. Capsorubin is a carotenoid found in peppers with multiple biological activities. Capsorubin (167 μM) inhibits lipid peroxidation induced by 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) in vitro. Capsorubin (1 μM) reduces UVB-induced DNA strand breaks and apoptosis in human dermal fibroblasts. Capsorubin also inhibits Epstein-Barr virus early antigen (EBV-EA) activation induced by phorbol 12-myristate 13-acetate in Raji cells, a marker of tumorigenesis.

HY-163858

Haspin-IN-4	Haspin Kinase	Cancer
Haspin-IN-4 (Compound 60) is a selective inhibitor of Haspin with an IC₅₀ value of 0.01 nM. Haspin-IN-4 possesses anticancer activity and can be used in cancer research .

HY-P991057

STI-6643	CD47	Cancer
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-118917

VX-148	IMPDH	Inflammation/Immunology
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with K_i values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .

HY-112608

CHMFL-PI3KD-317	PI3K	Cancer
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC₅₀, 62.6 nM), PI3Kβ (IC₅₀, 284 nM), PI3Kγ (IC₅₀, 202.7 nM), PIK3C2A (IC₅₀, >10000 nM), PIK3C2B (IC₅₀, 882.3 nM), VPS34 (IC₅₀, 1801.7 nM), PI4KIIIA (IC₅₀, 574.1 nM) and PI4KIIIB (IC₅₀, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC₅₀ of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells .

HY-P99736

Miptenalimab 1 Publications Verification BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-19826

Isofistularin-3	DNA Methyltransferase ADC Payload Autophagy Apoptosis	Cancer
Isofistularin-3 is a direct, DNA-competitive DNMT1 inhibitor, with an IC₅₀ of 13.5 μM. Isofistularin-3, as a DNA demethylating agent, induces cell cycle arrest and sensitization to TRAIL in cancer cells. Isofistularin-3 can be used as an ADC cytotoxin .

HY-114809

AL-1	Reactive Oxygen Species (ROS) NADPH Oxidase	Inflammation/Immunology Cancer
AL-1 is a potent O2 ^- generation inhibitor (IC₅₀ = 7.6 μM) through the inhibition of leukocytic NADPH oxidase. AL-1 inhibits 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced H₂O₂ production. AL-1 reduces tumor incidence in ICR mouse skin. AL-1 can be used for research on oxidative stress-related diseases including cancer .

HY-12137R

Volasertib (Standard) BI 6727 (Standard)	Polo-like Kinase (PLK) Apoptosis Reference Standards	Cancer
Volasertib (Standard) is the analytical standard of Volasertib. This product is intended for research and analytical applications. Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-104072

BRD4-IN-3	Epigenetic Reader Domain	Infection Inflammation/Immunology
BRD4-IN-3 (compound 141) is a potent BRD4 inhibitor with an IC₅₀ of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC₅₀ value of >1 µM .

HY-P991462

GBR-1342	CD38	Cancer
GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .

HY-N7507

Sempervirine	Others	Cancer
Sempervirine is an indole alkaloid isolated from Gelsemium sempervirens with anti-tumor activities. Sempervirine is against sempervirine-sensitive tumor cells with EC₅₀ values of 2.7 μM, 1.77 μM, and 1.96 μM for Raji, MDA-MB-231 and HeLa cells, respectively .

HY-136342

Antitumor agent-23	Others	Cancer
Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .

HY-143427

MALT1-IN-9	MALT1	Cancer
MALT1-IN-9 is a potent MALT1 protease inhibitor with a IC₅₀ of <500 nM in Raji MALT1-GloSensor cells. MALT1-IN-9 has anticancer effects (WO2021000855A1; Compound 5) .

HY-151381

hDHODH-IN-10	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-10 is a selective, potent and orally active hDHODH inhibitor, with an IC₅₀ value of 10.9 nM. hDHODH-IN-10 forms hydrogen bonds with key residues Arg136 and Gln47. hDHODH-IN-10 inhibits the proliferation of cancer cells. hDHODH-IN-10 can be used in the research of cancers, such as AML, colorectal cancer .

HY-163444

Apoptosis inducer 15	Apoptosis	Cancer
Apoptosis inducer 15 (Compound 3) induces cell apoptosis and cell cycle arrest at G2/M phase. Apoptosis inducer 15 is cytotoxicitic without causing DNA fragmentation .

HY-151808

JS25	Btk	Neurological Disease Inflammation/Immunology Cancer
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC₅₀ value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier .

HY-108352

HU 331 VCE 004	Topoisomerase	Cancer
HU 331 (HU 331) is a highly specific Topoisomerase II inhibitor with anticancer activity. HU 331 has shown promising inhibitory effects on human cancer cell lines in vitro and human tumor xenografts in nude mice in vivo .

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of PI3K/Akt pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies .

HY-147754

JAK3/BTK-IN-6	Btk JAK	Inflammation/Immunology
JAK3/BTK-IN-6 (compound 14h) is a potent BTK and JAK3 dual inhibitor, with IC₅₀ values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research .

HY-N19721

Brasimarin B	EBV	Infection Cancer
Brasimarin B is a 4-phenylcoumarin compound found in the stem bark of Calophyllum brasiliense. Brasimarin B inhibits TPA (HY-18739)-induced EBV-EA activation in Raji cells .

HY-N13723

Methyl lucidenate D	EBV	Cancer
Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation with an IC₅₀ of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention .

HY-171186

EAPB0202	Drug Derivative	Cancer
EAPB0202 is an imidazolium and quinoxaline derivative. EAPB0202 shows significant cytotoxicity to A375 human melanoma cell line with an IC₅₀ of 2.35 μM. EAPB0202 can be used in the study of cancer .

HY-N18238

11-Oxomogroside I A1	EBV	Cancer
11-Oxomogroside I A1 is a cucurbitane-type triterpenoid glycoside and also an EBV-EA inhibitor. 11-Oxomogroside I A1 exerts 100% inhibitory effect on the induction of EBV-EA. 11-Oxomogroside I A1 can be used for cancer research .

HY-183188

7-Methoxy-4H-chromen-4-one-o-carborane	Androgen Receptor COX	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
7-Methoxy-4H-chromen-4-one-o-carborane is an ER agonist and COX inhibitor with a COX-1 IC₅₀ of 3.0 μM, COX-2 IC₅₀ of 1.0 μM. 7-Methoxy-4H-chromen-4-one-o-carborane can be used for research on antimicrobial, anti-inflammatory, antitumor, neuroprotective, and estrogenic effects .

HY-N16810

Methyl 15-hydroxy-7-oxo-dehydroabietate	Drug Derivative	Others
Methyl 15-hydroxy-7-oxo-dehydroabietate is a natural diterpene.

HY-N17354

Glycocitrine II	EBV	Infection
Glycocitrine II is an acridone alkaloid. Glycocitrine II can be isolated from the Rutaceous plants. Glycocitrine II inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced EBV-EA activation .

HY-N18310

Robustaflavone 4′-methyl ether	Others	Cancer
Robustaflavone 4′-methyl ether is a biflavonoid compound that can be isolated from the whole plant of Selaginella gracillima. Robustaflavone 4′-methyl ether inhibits the growth of cancer cells. Robustaflavone 4′-methyl ether can be used in the research of EBV-transformed B-cell carcinoma and lung cancer .

HY-182314

JAK3-IN-20	JAK STAT Apoptosis	Cancer
JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC₅₀ of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib (HY-10227)-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis. JAK3-IN-20 can be used for the research of Bortezomib-resistant multiple myeloma .

HY-N16853

Diepiserratenediol	Drug Derivative	Others
Diepiserratenediol is a natural triterpene.

HY-N17638

7-Oxomogroside V	EBV NO Synthase	Infection Cancer
7-Oxomogroside V is a cucurbitane-type glycoside isolated from the fruits of Siraitia grosvenorii. 7-Oxomogroside V inhibits the activation of Epstein-Barr virus early antigen (EBV-EA) induced by TPA (HY-18739). 7-Oxomogroside V also exerts weak inhibitory effects on the activation of the nitric oxide donor NOR 1. 7-Oxomogroside V is applicable to tumor-related research .

HY-P991996

SM201	Fc Receptor (FcR)	Inflammation/Immunology
SM201 is a monoclonal antibody that targets FcγRIIB. SM201 specifically binds to FcγRIIB, enhances ITIM phosphorylation of FcγRIIB in an immune complex-dependent manner, and acts synergistically with immune complexes to amplify inhibitory signals. SM201 does not induce apoptosis, activate NK cells, or deplete B cells. SM201 can be used for the research of autoimmune diseases .

HY-P992176

ADU-1805	CD47	Cancer
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a K_d value of 11.0 × 10 ^-9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .

Cat. No.	Product Name	Target	Research Area	Image